You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
NOVO-118 as a therapeutic to promote remyelination in in vivo models of MS
SBC: NOVORON BIOSCIENCE INC Topic: NINDS7. Project Summary Multiple sclerosis (MS) is a neurodegenerative disease in which myelin of the central nervous system (CNS) is destroyed by a self-reactive immune response. This demyelination is accompanied by the death of the myelinating cells themselves, the oligodendrocytes. Repeated bouts of demyelination leave the denuded CNS neurons vulnerable to degradation and is the major cause of neuro ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Novel monoclonal antibody for single dose treatment of acute CNS injury
SBC: Oncosynergy, Inc. Topic: 999PROJECT SUMMARY Traumatic brain injury (TBI) represents a significant societal and economic impact. To date, there are no FDA- approved pharmacotherapies to prevent or reverse TBI. The standard of care in an emergency setting focuses first on stabilizing the patient and secondly on management of cerebral hemodynamics. The patient may undergo surgery to remove hematomas, repair skull fractures, and ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
A user-friendly scalable microfluidic platform for enhanced neuron-cell culture
SBC: Xona Microfluidics, Inc. Topic: NIMHDESCRIPTION (provided by applicant): Neuron-cell culture is widely used for studies in basic research, drug discovery, and toxicity testing. Traditional random cultures allow limited access to subcellular compartments (axons, dendrites, synapses) due to extensive and haphazard growth of neurons. Our long-term goal is to provide robust, user-friendly, and cost effective culture platforms that can o ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Targeting lipid rafts for treatment of migraine
SBC: RAFT PHARMACEUTICALS LLC Topic: NINDSPROJECT SUMMARY Migraine is a highly prevalent condition with an extraordinarily negative impact on quality of life and represents a heavy socioeconomic burden to the societyprimarily because of decreased working efficiency and workdays lostManagement of migraine has become increasingly pharmacological during recent yearsWhile several therapeutic options existmost of the prophylactic drugs current ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model
SBC: APPLIED GENETIC TECHNOLOGIES CORPORATION Topic: NDESCRIPTION provided by applicant Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors Patients with complete achromatopsia experience extreme light sensitivity and daytime blindness and best visual acuity under non bright light conditions is usually or worse and generally stable over time In addition to poor acuity hypersensit ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Pre-clinical evaluation of DT-001, a small molecule antagonist of MD2-TLR4 for utility in the treatment of pain.
SBC: Douleur Therapeutics Inc Topic: NINDSProject Summary AbstractUpwards ofmillion individuals are afflicted by chronic pain in the US alonewithmillion of these individuals suffering from neuropathic painOn a global scalechronic pain affectsbillion individualswithwho endure lower back painFrom a clinical perspectivethe International Association for the Study of Pain approximates thatinpatients present with painand on an annual basisinpat ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Advancing clemizole for hepatitis C: towards a pre-IND package
SBC: EIGER GROUP INTERNATIONAL, INC. Topic: NIAIDDESCRIPTION (provided by applicant): Over 150 million people worldwide are infected with the hepatitis C virus (HCV), which is an important cause of chronic liver disease. Current therapies are inadequate. Our long-term objective is to bring a new class of anti-HCV drugs to the clinic. We recently discovered and genetically validated a new target within the HCV non-structural protein NS4B, consist ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Evaluation of Staphylococcus aureus agr-based Quorum Sensing as Vaccine Candidate
SBC: SORRENTO THERAPEUTICS, INC. Topic: NIAIDDESCRIPTION (provided by applicant): In this proposal we lay out a comprehensive research plan to evaluate our passive vaccination strategies targeting Staphylococcus aureus/MRSA to prevent or treat infections associated with S. aureus/MRSA. With the emergence of highly antibiotic-resistant bacterial strains, most notably MRSA, new approaches for combating bacterial infections are desperately nee ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Immunotherapeutics to prevent HCV reinfection
SBC: Integrated Biotherapeutics, Inc. Topic: NIAIDDESCRIPTION (provided by applicant): Up to 170 million people worldwide are chronically infected with HCV Hepatitis C virus (HCV) putting the infected individuals at significant risk for cirrhosis, liver failure and liver cancer. End- stage liver diseasecaused by HCV is the leading indication of liver transplantation (LT) in the United States. However, reinfection with HCV occurs universally and ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Monoclonal antibodies targeting novel sites of vulnerability in marburg virus glycoprotein
SBC: Integrated Biotherapeutics, Inc. Topic: NIAIDFiloviruses, consisting of two major virus families including the ebolaviruses and marburgviruses (MARV and RAVV), cause periodic outbreaks of severe viral hemorrhagic fever with mortality rates as high as 90%. Since it is difficult to predict the species that would dominate future outbreaks, development of broadly protective therapeutics to prevent and manage future filovirus outbreaks is of high ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health